Investigation of semi-solid formulations for 3D printing of drugs after prolonged storage to mimic real-life applications

被引:39
作者
El Aita, Ilias [1 ]
Breitkreutz, Joerg [1 ]
Quodbach, Julian [1 ]
机构
[1] Heinrich Heine Univ Duesseldorf, Inst Pharmaceut & Biopharmaceut, Univ Str 1, D-40225 Dusseldorf, Germany
关键词
3D-printing; Levetiracetam; Hydroxypropyl methylcellulose; Pressure-assisted microsyringe (PAM); Micro extrusion; Sustained release; Individualized medicine; PHARMACEUTICAL EXCIPIENTS; RELEASE; FABRICATION; IMMEDIATE; TABLETS; MICROSYRINGE; DEPOSITION; SCAFFOLDS;
D O I
10.1016/j.ejps.2020.105266
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The implementation of tailor-made dosage forms is currently one of the biggest challenges in the health sector. Over the last years, different approaches have been introduced to provide an individual and precise dispensing of the appropriate dose of an active pharmaceutical ingredient (API). A more recent approach, which has been intensively researched in the last years, is 3D-printing of medicines. The aim of this work was to develop printing formulations free of organic solvents for a pressure-assisted microsyringe printing method (PAM), which should also be printable over several days of storage. Furthermore, the printed dosage forms should provide a sustained release of the incorporated API. A mixture of polyvinyl acetate/polyvinylpyrrolidone copolymer (PVAc-PVP), hydroxypropyl methylcellulose (HPMC) and highly dispersed silicon dioxide (SiO2) was found to be a feasible polymer matrix to achieve a sustained drug release. Levetiracetam (LEV) was used as model drug. The printed formulations were analyzed regarding mass variation, friability and thickness. Furthermore, the dissolution behavior of freshly printed tablets and tablets printed from stored printing formulations were investigated. The dissolution profiles indicate that the dissolution of LEV could be modified by varying the amount of HPMC and by changing the infill design of tablets. Tablet-like geometries with an infill design of 0.35 mm and 5% HPMC released 50% of the incorporated drug after 4 h, while for tablets with a higher HPMC amount the release was decreased (10% HPMC: 5.5 h; 15% HPMC: 8 h). All printed tablets exhibit a friability < 0.5%, indicating that PAM printing is suitable for the manufacturing of tablets with a high structural integrity. Furthermore, this study demonstrates the ability of producing tablets with a uniform content and mass using PAM printing.
引用
收藏
页数:9
相关论文
共 34 条
  • [1] ALDERMAN D A, 1984, International Journal of Pharmaceutical Technology and Product Manufacture, V5, P1
  • [2] Emergence of 3D Printed Dosage Forms: Opportunities and Challenges
    Alhnan, Mohamed A.
    Okwuosa, Tochukwu C.
    Sadia, Muzna
    Wan, Ka-Wai
    Ahmed, Waqar
    Arafat, Basel
    [J]. PHARMACEUTICAL RESEARCH, 2016, 33 (08) : 1817 - 1832
  • [3] [Anonymous], EUR J PHARM BIOPHARM
  • [4] Ways to minimize adverse drug reactions - Individualized doses and common sense are key
    Cohen, JS
    [J]. POSTGRADUATE MEDICINE, 1999, 106 (03) : 163 - +
  • [5] Commission E.P., 2016, RES SOLV
  • [6] Modeling and comparison of dissolution profiles
    Costa, P
    Manuel, J
    Lobo, S
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) : 123 - 133
  • [7] Development of modified release 3D printed tablets (printlets) with pharmaceutical excipients using additive manufacturing
    Goyanes, Alvaro
    Fina, Fabrizio
    Martorana, Annalisa
    Sedough, Daniel
    Gaisford, Simon
    Basit, Abdul W.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 527 (1-2) : 21 - 30
  • [8] Fused-filament 3D printing (3DP) for fabrication of tablets
    Goyanes, Alvaro
    Buanz, Asma B. M.
    Basit, Abdul W.
    Gaisford, Simon
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 476 (1-2) : 88 - 92
  • [9] Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine
    Guo YongLi
    Shi LeMing
    Hong HuiXiao
    Su ZhenQiang
    Fuscoe, James
    Ning BaiTang
    [J]. SCIENCE CHINA-LIFE SCIENCES, 2013, 56 (02) : 119 - 124
  • [10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Validation of analytical procedures: Text and methodology Q2(R1)